XXXX immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.

@entity12877 @entity1 @entity263 @entity1885 @entity27949 @entity189 @entity982 @entity1412 @entity5436
@entity12877 is a recently described, @entity263 -specific gene that encodes a protein involved in the beta-oxidation of @entity27949 . A recent study has shown that immunohistochemical detection of @entity12877 gene product is a sensitive and specific marker of @entity263 in formalin-fixed, @entity982 -embedded tissues. We performed a detailed analysis of @entity12877 protein expression in a large series of prostate and bladder specimens with special emphasis on staining in specific morphologic patterns of @entity263 , posthormonal and radiation therapy cases, and invasive @entity189 . A total of 366 prostate needle core biopsies from 124 @entity1 with @entity263 , 10 biopsies from 2 @entity1 without @entity263 , 28 prostatectomy specimens (16 with specific morphologic patterns, 7 posthormonal therapy and 5 postradiation therapy specimens), 5 bladder specimens with invasive @entity189 , and a single transurethral resection specimen from a @entity1 with hormonally treated @entity263 and invasive @entity189 were stained with @entity12877 monoclonal antibody at a 1:250 dilution using standard heat-induced epitope retrieval and avidin- @entity1885 technique. Extent (0, no staining; 1+, 1-10% staining; 2+, 11-50% staining; 3+, > or =51% staining) and location (luminal, subluminal, and diffuse cytoplasmic) of immunoreactivity in @entity189 and benign tissues were recorded. A total of 153 of 186 biopsies (82%) with @entity263 stained for @entity12877 . Pseudohyperplastic, @entity263 stained similarly, as did cases treated with hormone or radiotherapy. In 81 of 377 (21%) foci of benign prostatic tissue there was staining that was almost always focal, faint, and noncircumferential. Seminal vesicles did not stain for @entity12877 . Five of six (83%) specimens with invasive @entity189 had 2+ staining and one case had focal staining. We conclude that immunohistochemistry for @entity12877 has potential utility in the diagnosis of @entity263 , including those treated by hormones and radiation. Circumferential luminal to subluminal and diffuse cytoplasmic staining is the most specific staining pattern for @entity263 and is almost never associated with benign prostatic tissue. However, a negative @entity12877 immunostain does not automatically rule out @entity263 , as 18% of cases were negative. Additionally, occasional benign glands, high-grade @entity5436 , atypical @entity1412 , and @entity189 may express @entity12877 . Therefore, we think that @entity12877 is best used only in conjunction with strict light microscopic correlation and preferably with high molecular weight cytokeratin immunostaining.
